Wyeth-Ayerst Premarin delta 8,9 component should be classified as active ingredient -- amended petition.
WYETH-AYERST PREMARIN DELTA 8,9-DHES SHOULD BE CONSIDERED ACTIVE INGREDIENT, "the same as estrone sulfate and equilin sulfate," the company says in a recent letter to FDA amending its November 1994 citizen petition. In defining the components of Premarin, a February 1991 Generic Drugs Advisory Committee classified delta 8,9-dehydroestrone sulfate as a signal impurity, subject to a limit test. Wyeth-Ayerst's contention since then has been that delta 8,9-DHES should be reclassified as a required "concomitant component."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth